Olanzapine is evaluated across numerous clinical trials investigating central nervous system and supportive care indications, primarily targeting schizophrenia, schizoaffective disorder, treatment-resistant depression, bipolar I disorder, chemotherapy-induced nausea and vomiting, and treatment-associated weight gain. Spanning Early Phase 1 through Phase 4, these studies include recruiting, completed, terminated, and not yet recruiting trials. Clinical evaluation is supported by both major pharmaceutical sponsors and academic institutions.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07152184 | NOT_YET_RECRUITING | Patient With Schizophrenia Spectrum Disorder; NLM Classification WM 203, Psychology:Schizophrenic Psychology; Schizophrenia Spectrum and Other Psychotic Disorders |
University Hospital, Strasbourg, France |
2026-10-01 | PHASE2 |
| NCT06995508 | RECRUITING | Cancer-Associated Anorexia; Head and Neck Squamous Cell Carcinoma; Neck Squamous Cell Carcinoma of Unknown Primary |
Roswell Park Cancer Institute |
2025-12-24 | PHASE2 |
| NCT07722806 | NOT_YET_RECRUITING | Cancer, Advanced Solid Tumors; Malnutrition |
Kantonsspital Winterthur KSW |
2026-08 | PHASE2 |
| NCT07581405 | NOT_YET_RECRUITING | Gastric Adenocarcinoma; Gastric Cancer |
University of Illinois at Chicago |
2026-09 | PHASE2 |
| NCT07442890 | NOT_YET_RECRUITING | Lung Cancer |
Henan Cancer Hospital |
2026-04-30 | |
| NCT07208305 | RECRUITING | Nausea; Vomiting |
Affiliated Hospital of Qinghai University |
2026-02-03 | PHASE3 |
| NCT07047651 | ACTIVE_NOT_RECRUITING | Treatment Resistant Schizophrenia; Treatment Resistant Bipolar Disorder |
Dr. Stavroula Rakitzi |
2025-06-04 | PHASE4 |
| NCT05635227 | RECRUITING | Coronary Artery Disease; Aortic Valve Disease |
Rigshospitalet, Denmark |
2022-11-10 | |
| NCT07565428 | RECRUITING | Negative Symptoms of Schizophrenia |
Minerva Neurosciences |
2026-04-23 | PHASE3 |
| NCT07699276 | RECRUITING | Cancer (Solid Tumors); Vomiting; Cisplatin; Olanzapine |
Mahidol University |
2026-02-10 | PHASE2 |
| NCT06588413 | RECRUITING | Multiple Myeloma; Autologous Stem Cell Transplantation |
Augusta University |
2024-09-17 | PHASE3 |
| NCT04478838 | RECRUITING | Schizophrenia and Related Disorders; Drug Administration Schedule; Drug Therapy; Antipsychotic Agents |
Centre for Addiction and Mental Health |
2022-06-06 | PHASE4 |
| NCT07743827 | RECRUITING | Olanzapine; Breast Cancer; Dexamethasone |
Alexandria University |
2026-05-10 | |
| NCT05895838 | RECRUITING | Out-Of-Hospital Cardiac Arrest; Post-Cardiac Arrest Syndrome |
Christian Hassager |
2023-06-16 | PHASE3 |
| NCT07413809 | RECRUITING | Multiple Myeloma |
The Affiliated People's Hospital of Ningbo University |
2025-10-31 | PHASE3 |
| NCT07662200 | NOT_YET_RECRUITING | Germ Cell Cancer |
Ottawa Hospital Research Institute |
2026-08 | EARLY_PHASE1 |
| NCT05705492 | RECRUITING | Advanced Malignant Solid Neoplasm; Advanced Biliary Tract Carcinoma; Advanced Esophageal Carcinoma; Metastatic Esophageal Carcinoma; Locally Advanced Colorectal Carcinoma; Locally Advanced Esophageal Carcinoma; Locally Advanced Gastric Carcinoma; Metastatic Colorectal Carcinoma (mCRC); Advanced Lung Carcinoma; Locally Advanced Hepatocellular Carcinoma |
OHSU Knight Cancer Institute |
2024-07-17 | PHASE2 |
| NCT07455955 | RECRUITING | Breast Cancer |
Chinese University of Hong Kong |
2026-03-31 | PHASE2 |
| NCT06821945 | RECRUITING | Schizophrenia |
Boryung Pharmaceutical Co., Ltd |
2025-05-30 | PHASE2 |
| NCT06740890 | RECRUITING | Schizophenia Disorder; Schizoaffective Disorder; Bipolar Disorder I or II; Bipolar Disorder NOS |
New York State Psychiatric Institute |
2025-06-26 | PHASE4 |
| NCT06338683 | RECRUITING | Advanced Cancer; Olanzapine; Progression Free Survival |
Qinghai Red Cross Hospital |
2024-03-20 | PHASE3 |
| NCT03781115 | ACTIVE_NOT_RECRUITING | Schizophrenia |
University of Arizona |
2017-11-20 | PHASE1 |
| NCT05814640 | RECRUITING | Depression; Sequestra |
First Affiliated Hospital of Chongqing Medical University |
2023-02-20 | PHASE1; PHASE2 |
| NCT07633236 | RECRUITING | Oncology Patients Receiving Chemotherapy; Cachexia-Anorexia Syndrome; Oncology |
Blokhin's Russian Cancer Research Center |
2025-03-28 | PHASE3 |
| NCT06554613 | RECRUITING | Non-Small Cell Lung Cancer |
Second Affiliated Hospital of Nanchang University |
2024-07-02 | PHASE2 |
| NCT05170919 | ENROLLING_BY_INVITATION | Anorexia Nervosa with Significantly Low Body Weight |
Englewood Hospital and Medical Center |
2022-01-20 | PHASE2 |
| NCT06200181 | RECRUITING | Misuse, Opioid |
M.D. Anderson Cancer Center |
2024-04-02 | PHASE3 |
| NCT07246187 | RECRUITING | Cannabinoid Hyperemesis Syndrome |
Mercy Bon Secours Saint Vincent Medical Center |
2025-11-06 | PHASE3 |
| NCT06200168 | RECRUITING | Electroacupuncture; Olanzapine-contained Four-drug Antiemetic; Nausea and Vomiting |
Jiuda Zhao |
2024-01-16 | PHASE3 |
| NCT07482891 | RECRUITING | Chemotherapy-induced Nausea and Vomiting |
Shanghai 6th People's Hospital |
2026-03-10 | PHASE4 |
| NCT05303064 | RECRUITING | Schizophrenia; Bipolar I Disorder |
Alkermes, Inc. |
2022-06-30 | PHASE3 |
| NCT06251635 | RECRUITING | Insulin Resistance; Menstrual Cycle; Type 2 Diabetes; Antipsychotics |
Centre for Addiction and Mental Health |
2024-06-03 | |
| NCT03741478 | ACTIVE_NOT_RECRUITING | Healthy Controls |
Centre for Addiction and Mental Health |
2019-10-22 | PHASE1 |
| NCT07035821 | NOT_YET_RECRUITING | Breakthrough Chemotherapy-Induced Vomiting (CIV) in Pediatric Patients; Pediatric Cancer |
Shanghai Children's Medical Center |
2025-07-01 | PHASE3 |
| NCT05669742 | RECRUITING | Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics |
Tanta University |
2023-05-25 | PHASE3 |
| NCT04939090 | ACTIVE_NOT_RECRUITING | Advanced Malignant Solid Neoplasm; Anorexia; Hematopoietic and Lymphoid Cell Neoplasm |
Alliance for Clinical Trials in Oncology |
2022-01-03 | PHASE3 |
| NCT06649214 | NOT_YET_RECRUITING | Schizophrenia |
Qilu Pharmaceutical Co., Ltd. |
2024-11 | PHASE3 |
| NCT03118986 | COMPLETED | Vomiting in Infants and/or Children; Nausea; Hematopoietic System--Cancer; Oncology |
The Hospital for Sick Children |
2017-08-10 | PHASE2 |
| NCT04892199 | ACTIVE_NOT_RECRUITING | Metabolic Disturbance; Schizophrenia; Type 2 Diabetes; Clozapine; GLP-1; Olanzapine |
Anders Fink-Jensen, MD, DMSci |
2021-09-01 | PHASE4 |
| NCT06517199 | UNKNOWN | Anorexia; Cachexia |
Mahidol University |
2024-01-22 | PHASE3 |
| NCT06850454 | RECRUITING | Chemotherapy Induced Nausea and Vomiting |
Mahidol University |
2025-01-10 | PHASE3 |
| NCT05676294 | COMPLETED | Postoperative Nausea and Vomiting |
Yale University |
2023-06-26 | PHASE2 |
| NCT06315283 | COMPLETED | Schizophrenia |
Teva Branded Pharmaceutical Products R&D LLC |
2024-03-20 | PHASE1 |
| NCT06175273 | COMPLETED | Pediatric Cancer; Nutrition Related Cancer; Nutrition Aspect of Cancer; Muscle Loss; Malnutrition, Child |
Corey Hawes |
2024-01-31 | PHASE2; PHASE3 |
| NCT06331520 | COMPLETED | Chemotherapy-induced Nausea and Vomiting; Highly Emetogenic Chemotherapy |
Fudan University |
2024-05-01 | PHASE3 |
| NCT05590923 | TERMINATED | Chemotherapy-induced Nausea and Vomiting |
The Guthrie Clinic |
2022-12-07 | PHASE4 |
| NCT05964647 | COMPLETED | Healthy |
University Hospital, Basel, Switzerland |
2024-02-01 | PHASE1 |
| NCT06253546 | COMPLETED | Schizophrenia |
Teva Branded Pharmaceutical Products R&D LLC |
2024-03-28 | PHASE1 |
| NCT06500234 | RECRUITING | Nutrition Disorders; Immunotherapy; Cancer; Survival, Prosthesis |
Qingdao Central Hospital |
2024-06-01 | PHASE3 |
| NCT06288854 | UNKNOWN | Weight Gain |
Department of Medical Services Ministry of Public Health of Thailand |
2024-04-03 | |
| NCT04529226 | UNKNOWN | Psychosis; Intellectual Disability |
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
2020-11-26 | PHASE2 |
| NCT06319170 | COMPLETED | Schizophrenia, Schizoaffective Disorder |
Teva Branded Pharmaceutical Products R&D LLC |
2024-03-28 | PHASE1 |
| NCT07190482 | COMPLETED | Tinnitus; Tinnitus, Subjective |
University of Sao Paulo |
2023-10-01 | PHASE1 |
| NCT04833023 | UNKNOWN | Haloperidol; Advanced Cancer; Hyperactive Delirium; Olanzapine; End-stage Organ Disease |
Tan Tock Seng Hospital |
2022-05-18 | PHASE3 |
| NCT04518319 | SUSPENDED | Schizophrenia |
Shanghai Mental Health Center |
2020-10-01 | PHASE2 |
| NCT02088060 | TERMINATED | Schizophrenia |
Central Institute of Mental Health, Mannheim |
2015-12-08 | PHASE2 |
| NCT05803642 | UNKNOWN | Acute Agitation |
Qilu Pharmaceutical Co., Ltd. |
2023-03-28 | PHASE3 |
| NCT04750395 | UNKNOWN | Delirium; Terminal Illness |
HCA Hospice Care |
2021-09-01 | PHASE2 |
| NCT05805800 | COMPLETED | Chemotherapy-induced Nausea and Vomiting |
Xingchen Peng |
2023-04-15 | PHASE3 |
| NCT03367572 | COMPLETED | Breast Carcinoma |
University of Rochester NCORP Research Base |
2018-04-19 | PHASE3 |
| NCT06288854 | Not yet recruiting | Weight Gain |
Rajavithi Hospital |
2024-04-03 | Not Applicable |
| NCT05693935 | COMPLETED | Schizophrenia |
Teva Branded Pharmaceutical Products R&D LLC |
2023-01-24 | PHASE3 |
| NCT06357104 | COMPLETED | COVID-19 Vaccine Adverse Reaction |
Pachankis, Yang I., M.D. |
2024-02-26 | PHASE4 |
| NCT06133114 | WITHDRAWN | Suicide Crisis Syndrome; Psychological Distress |
Icahn School of Medicine at Mount Sinai |
2024-03-13 | PHASE4 |
| NCT05346731 | UNKNOWN | Chemotherapy-induced Nausea and Vomiting |
Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
2022-04-01 | PHASE3 |
| NCT06319170 | Recruiting | Schizophrenia Schizoaffective Disorder |
Teva Branded Pharmaceutical Products R&D Inc. |
2024-03-28 | Phase 1 |
| NCT06315283 | Recruiting | Schizophrenia |
Teva Branded Pharmaceutical Products R&D Inc. |
2024-03-20 | Phase 1 |
| NCT06253546 | Recruiting | Schizophrenia |
Teva Branded Pharmaceutical Products R&D Inc. |
2024-03-28 | Phase 1 |
| NCT05542264 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2022-11-15 | PHASE1 |
| NCT06107803 | COMPLETED | Negative Symptoms in Schizophrenia |
Minerva Neurosciences |
2023-10-13 | PHASE1 |
| NCT04503668 | TERMINATED | Gynecologic Cancer |
University of Michigan Rogel Cancer Center |
2020-12-28 | PHASE3 |
| NCT05244577 | UNKNOWN | Olanzapine; CINV; Testicular Cancer by AJCC V6 and V7 Stage; Cisplatin |
Shi Yanxia |
2022-01-18 | PHASE3 |
| NCT06065722 | UNKNOWN | Chemotherapy Induced Nausea and Vomiting |
Simon Williamson Clinic |
2023-09-09 | PHASE2 |
| NCT05403580 | WITHDRAWN | Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm |
Mayo Clinic |
2022-06-03 | PHASE3 |
| NCT04341467 | UNKNOWN | BPSD; Amisulpride; Olanzapine; Dementia of the Alzheimer Type |
Tianjin Anding Hospital |
2019-12-01 | |
| NCT06600477 | COMPLETED | Healthy |
Neurelis, Inc. |
2023-10-16 | PHASE1 |
| NCT03030417 | COMPLETED | Solid Tumors; Lymphoma |
National Cancer Institute (NCI) |
2017-02-27 | PHASE1 |
| NCT02708394 | COMPLETED | Adverse Effect of Other Antipsychotics and Neuroleptics; Insulin Resistance |
Wayne State University |
2017-02-01 | EARLY_PHASE1 |
| NCT04216329 | ACTIVE_NOT_RECRUITING | Gliosarcoma; Newly Diagnosed; Glioblastoma |
National Cancer Institute (NCI) |
2020-07-07 | PHASE1 |
| NCT05402111 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2022-06-13 | PHASE1 |
| NCT03510325 | COMPLETED | Schizophrenia |
Shanghai Mental Health Center |
2019-02-12 | PHASE3 |
| NCT05242874 | COMPLETED | Chemotherapy-induced Nausea and Vomiting |
Henan Cancer Hospital |
2022-02-01 | PHASE3 |
| NCT05857566 | COMPLETED | Drug-induced Weight Gain |
Response Pharmaceuticals |
2023-05-16 | PHASE1 |
| NCT04718727 | COMPLETED | Postoperative Nausea |
Amani Hassan Abdel-Wahab |
2021-03-15 | PHASE1; PHASE2 |
| NCT05179772 | WITHDRAWN | Opioid Use Disorder |
University of Pennsylvania |
2022-07-28 | PHASE2 |
| NCT05202275 | UNKNOWN | Nausea; Vomiting; Head and Neck Squamous Cell Carcinoma; Radiotherapy Side Effect |
Chinese Academy of Medical Sciences |
2020-12-01 | PHASE2 |
| NCT05243251 | COMPLETED | Anorexia |
Cairo University |
2021-12-25 | PHASE3 |
| NCT05547100 | COMPLETED | Focus of Study is on Healthy Lactating Women |
Alkermes, Inc. |
2022-09-14 | PHASE1 |
| NCT05213143 | TERMINATED | Schizophrenia |
Marubeni Pharmaceuticals (Suzhou) Co., Ltd. |
2021-12-30 | PHASE4 |
| NCT03571126 | UNKNOWN | Chemotherapy-induced Nausea and Vomiting; Lung Cancer |
Zunyi Medical College |
2019-05-09 | PHASE4 |
| NCT04437017 | COMPLETED | Chemotherapy-induced Nausea and Vomiting |
Fifth Affiliated Hospital, Sun Yat-Sen University |
2020-02-03 | PHASE3 |
| NCT04535141 | COMPLETED | Chemotherapy-induced Nausea and Vomiting |
UNC Lineberger Comprehensive Cancer Center |
2020-08-18 | PHASE3 |
| NCT02939287 | COMPLETED | Nausea; Vomiting |
Rush University Medical Center |
2017-09-23 | PHASE3 |
| NCT04669132 | COMPLETED | Nausea Post Chemotherapy |
Instituto Brasileiro de Controle do Cancer |
2020-12-17 | PHASE2 |
| NCT03187769 | COMPLETED | Schizophrenia; Schizophreniform Disorders; Bipolar I Disorder |
Alkermes, Inc. |
2017-06-08 | PHASE3 |
| NCT03578081 | COMPLETED | Malignant Neoplasm |
Alliance for Clinical Trials in Oncology |
2018-11-20 | PHASE3 |
| NCT03857581 | UNKNOWN | Psychosis; Substance Use Disorders |
Augusta University |
2020-07 | PHASE4 |
| NCT04232423 | COMPLETED | Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis |
Department of Medical Services Ministry of Public Health of Thailand |
2020-03-01 | PHASE3 |
| NCT04876521 | COMPLETED | Post-Schizophrenic Depression |
All India Institute of Medical Sciences, Bhubaneswar |
2019-10-14 | PHASE4 |
| NCT06200584 | COMPLETED | Antipsychotics and Neuroleptics Toxicity |
Dr Rabia Arshad |
2021-01-01 | |
| NCT03960151 | WITHDRAWN | Germ Cell Tumor |
Costantine Albany |
2018-05 | PHASE2 |
| NCT03575637 | UNKNOWN | Gastric Cancer |
Peking University |
2018-07 | PHASE2 |
| NCT03079219 | COMPLETED | Breast Cancer |
CCTU |
2017-03-23 | PHASE3 |
| NCT03631004 | COMPLETED | Postoperative Nausea; Postoperative Nausea and Vomiting |
Instituto do Cancer do Estado de São Paulo |
2018-10-01 | PHASE2; PHASE3 |
| NCT04536558 | UNKNOWN | Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy |
Sun Yat-sen University |
2020-10-01 | PHASE3 |
| NCT05123976 | COMPLETED | Pharmacokinetics |
Joint Stock Company "Farmak" |
2020-10-21 | PHASE1 |
| NCT03679182 | UNKNOWN | Nausea; Vomiting; End Stage Cancer |
Khon Kaen University |
2018-09-01 | PHASE2 |
| NCT03876938 | UNKNOWN | Antiemetic for Highly Emetogenic Chemotherapy |
Mahidol University |
2019-03-01 | PHASE3 |
| NCT03790085 | UNKNOWN | Schizophrenia; Major Depressive Disorder; Anxiety Disorders |
Tianjin Medical University General Hospital |
2018-09-01 | EARLY_PHASE1 |
| NCT03877562 | COMPLETED | Antipsychotic-induced Weight Gain |
Corcept Therapeutics |
2019-04-01 | PHASE1 |
| NCT04181385 | UNKNOWN | Healthy |
University Health Network, Toronto |
2019-01-01 | PHASE2; PHASE3 |
| NCT04075955 | COMPLETED | Chemotherapy-induced Nausea and Vomiting |
CR-CSSS Champlain-Charles-Le Moyne |
2019-04-29 | PHASE3 |
| NCT02861859 | COMPLETED | Breast Cancer |
Ottawa Hospital Research Institute |
2016-12 | PHASE3 |
| NCT02431702 | COMPLETED | Schizophrenia; Psychotic Disorders |
Janssen Scientific Affairs, LLC |
2015-07-08 | PHASE3 |
| NCT02536846 | COMPLETED | Healthy |
Dost Ongur |
2017-11-17 | PHASE4 |
| NCT03557931 | COMPLETED | Schizophrenia |
Astellas Pharma Global Development, Inc. |
2018-07-13 | PHASE2 |
| NCT02755116 | COMPLETED | Postoperative Nausea and Vomiting |
Jaime B Hyman |
2016-04 | PHASE2 |
| NCT02380118 | TERMINATED | Acute Agitation, Behavioural Emergency |
The University of Hong Kong |
2014-12 | PHASE4 |
| NCT03219710 | COMPLETED | Chemotherapy-induced Nausea and Vomiting |
All India Institute of Medical Sciences |
2017-07-01 | PHASE3 |
| NCT03137121 | COMPLETED | Advanced Cancer |
University of Alabama at Birmingham |
2017-07-12 | PHASE2; PHASE3 |
| NCT01625923 | TERMINATED | Idiopathic Gastroparesis |
University of Michigan |
2013-01 | |
| NCT02562287 | UNKNOWN | Bipolar Disorder |
Hospital de Clinicas de Porto Alegre |
2015-10 | PHASE4 |
| NCT03478605 | UNKNOWN | Emesis; Vomiting; Nausea Post Chemotherapy; Nausea; Chemotherapy-induced Nausea and Vomiting |
Blokhin's Russian Cancer Research Center |
2018-05-25 | PHASE2 |
| NCT03568500 | COMPLETED | Schizophrenia; Schizoaffective Disorder; First Episode Psychosis |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2018-05-21 | PHASE4 |
| NCT01609153 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Heinrich-Heine University, Duesseldorf |
2012-06 | PHASE4 |
| NCT02287259 | COMPLETED | Bipolar Disorder |
Tadashi Hasegawa |
2014-11 | PHASE4 |
| NCT03230864 | TERMINATED | Treatment-resistant Schizophrenia |
H. Lundbeck A/S |
2017-07-20 | PHASE3 |
| NCT04076371 | COMPLETED | Schizophrenia |
Beijing HuiLongGuan Hospital |
2012-01 | |
| NCT02435654 | COMPLETED | Early-onset Schizophrenia |
Kunming Medical University |
2015-08 | PHASE4 |
| NCT02694328 | COMPLETED | Schizophrenia |
Alkermes, Inc. |
2016-03-02 | PHASE3 |
| NCT03624322 | COMPLETED | Acute Agitation |
Impel Pharmaceuticals |
2018-08-05 | PHASE1 |
| NCT02717195 | COMPLETED | Schizophrenia |
H. Lundbeck A/S |
2016-04 | PHASE3 |
| NCT03246620 | TERMINATED | Acute Agitation; Behavioural Emergency |
The University of Hong Kong |
2017-09-01 | PHASE4 |
| NCT03066622 | COMPLETED | Headache |
HealthPartners Institute |
2016-07 | PHASE4 |
| NCT03304457 | COMPLETED | Schizophrenia |
All India Institute of Medical Sciences, Bhubaneswar |
2017-08-25 | PHASE4 |
| NCT02282085 | UNKNOWN | Schizophrenia |
Matt Byerly |
2014-12 | PHASE4 |
| NCT02635984 | COMPLETED | Complications of Bone Marrow Transplant; Hematologic Neoplasms |
Augusta University |
2015-11 | PHASE3 |
| NCT01446328 | COMPLETED | Schizophrenia; Psychotic Disorders |
Haukeland University Hospital |
2011-10 | PHASE4 |
| NCT01427608 | COMPLETED | Psychotic Depression |
Weill Medical College of Cornell University |
2011-10 | PHASE4 |
| NCT02970643 | UNKNOWN | Chemotherapy-induced Nausea and Vomiting |
Hee Jun Kim |
2016-07 | |
| NCT02918825 | COMPLETED | Schizophrenia |
Beijing HuiLongGuan Hospital |
2016-09-01 | |
| NCT02051387 | COMPLETED | Schizophrenia |
Central Institute of Mental Health, Mannheim |
2013-01 | PHASE1 |
| NCT02922426 | COMPLETED | Healthy Volunteers |
Alkermes, Inc. |
2016-09 | PHASE1 |
| NCT02374567 | TERMINATED | Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders |
Hannover Medical School |
2015-01 | PHASE3 |
| NCT02643355 | COMPLETED | Substance Withdrawal Syndrome |
Hennepin Healthcare Research Institute |
2015-11 | |
| NCT02634346 | COMPLETED | Schizophrenia |
Alkermes, Inc. |
2015-12 | PHASE3 |
| NCT02007928 | COMPLETED | Dissociative Disorders; Schizophrenia |
Centre Hospitalier Universitaire de Nice |
2013-04 | |
| NCT00632645 | COMPLETED | Huntington Disease |
Assistance Publique - Hôpitaux de Paris |
2009-04 | PHASE3 |
| NCT01539733 | COMPLETED | Delirium; Advanced Cancer |
Amsterdam UMC, location VUmc |
2010-03 | |
| NCT02161718 | COMPLETED | Schizophrenia; Alcohol Use Disorder |
Alkermes, Inc. |
2014-05 | PHASE2 |
| NCT01185743 | COMPLETED | Schizophrenia; Diabetes |
Medical University of Vienna |
2010-07 | PHASE4 |
| NCT03019887 | COMPLETED | Schizophrenia Relapse |
Juntendo University |
2011-04 | |
| NCT02850445 | UNKNOWN | Schizophrenia |
Guangzhou Psychiatric Hospital |
2012-01 | |
| NCT02650102 | UNKNOWN | Schizophrenia |
Shanxi Medical University |
2013-01 | PHASE1; PHASE2 |
| NCT02634463 | COMPLETED | Immunoassay; Antipsychotic |
Janssen Research & Development, LLC |
2015-11-09 | PHASE1 |
| NCT02484911 | COMPLETED | Chemotherapy-induced Nausea and Vomiting |
First Affiliated Hospital of Harbin Medical University |
2015-05 | PHASE3 |
| NCT02307396 | COMPLETED | Schizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders |
Technical University of Munich |
2015-02-01 | PHASE4 |
| NCT01170117 | COMPLETED | Anorexia Nervosa |
New York State Psychiatric Institute |
2010-08 | |
| NCT01248195 | COMPLETED | Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder |
Rene Kahn |
2011-05 | PHASE4 |
| NCT02704962 | COMPLETED | Schizophrenia |
Kaohsiung Kai-Suan Psychiatric Hospital |
2012-01 | PHASE4 |
| NCT03216941 | COMPLETED | Psychomotor Agitation; Psychiatric Disorder; Emergency Psychiatric; Tranquilizers |
Universidad Nacional de Rosario |
2015-01-01 | PHASE4 |
| NCT02462473 | TERMINATED | Schizophrenia; Schizoaffective Disorder |
Janssen Research & Development, LLC |
2015-05 | PHASE2 |
| NCT02129478 | COMPLETED | Chemotherapy-induced Nausea and Vomiting |
The Hospital for Sick Children |
2014-03 | PHASE2 |
| NCT01893229 | UNKNOWN | Bipolar Disorder |
Guiyun Xu |
2013-09 | PHASE4 |
| NCT00202293 | COMPLETED | Bipolar Disorder; Schizoaffective Disorder |
Melbourne Health |
2001-10-01 | PHASE4 |
| NCT01687478 | TERMINATED | Treatment Resistant Depression |
Eli Lilly and Company |
2012-09 | PHASE3 |
| NCT02290470 | UNKNOWN | Nausea; Vomiting |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2014-04 | PHASE2 |
| NCT02400866 | UNKNOWN | Cancer |
Korean South West Oncology Group |
2015-05 | PHASE2 |
| NCT00716755 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Delusional Disorder; Psychotic Disorder |
Centre for Addiction and Mental Health |
2009-10 | |
| NCT02593734 | COMPLETED | Schizophrenia; Mood Disorders,; Anxiety Disorder |
University of Ghana Medical School |
2013-07 | PHASE4 |
| NCT00845507 | COMPLETED | Weight Gain |
University of Cincinnati |
2008-12 | PHASE4 |
| NCT02116530 | COMPLETED | Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific |
Alliance for Clinical Trials in Oncology |
2014-08-20 | PHASE3 |
| NCT01617200 | COMPLETED | Schizophrenia |
Forest Laboratories |
2012-12 | PHASE3 |
| NCT02097823 | COMPLETED | Chemotherapy Induced Nausea and Vomiting |
Indiana University |
2014-02 | PHASE2 |
| NCT02137616 | UNKNOWN | Psychotic Disorders |
Central South University |
2012-06 | |
| NCT02040883 | UNKNOWN | Schizophrenia |
Qingyun Yin |
2014-02 | PHASE4 |
| NCT02447835 | COMPLETED | Normal Non-fluency |
Michael Rickels |
2012-08 | PHASE1 |
| NCT01903837 | COMPLETED | Schizophrenia |
Alkermes, Inc. |
2013-06 | PHASE2 |
| NCT02087579 | COMPLETED | Psychotic Disorders; Schizophrenia; Bipolar Disorder; Depressive Disorder |
Janssen Research & Development, LLC |
2014-02 | PHASE1 |
| NCT01617187 | COMPLETED | Schizophrenia |
Organon and Co |
2012-12-04 | PHASE3 |
| NCT01920802 | COMPLETED | Healthy |
New York State Psychiatric Institute |
2012-11 | PHASE4 |
| NCT01389908 | UNKNOWN | Schizophrenia; Schizoaffective Disorders |
Shalvata Mental Health Center |
2011-06 | |
| NCT02192723 | COMPLETED | Schizophrenia |
Beijing HuiLongGuan Hospital |
2012-06 | |
| NCT01029769 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder |
Technical University of Munich |
2009-12 | |
| NCT00806234 | COMPLETED | Psychotic Disorders |
Johns Hopkins University |
2009-01 | PHASE4 |
| NCT00489593 | COMPLETED | Advanced Cancer; Weight Loss |
M.D. Anderson Cancer Center |
2006-10 | PHASE1 |
| NCT01157351 | COMPLETED | Schizophrenia |
Janssen Scientific Affairs, LLC |
2010-05 | PHASE4 |
| NCT01148264 | TERMINATED | Emesis |
Karin Jordan |
2010-07 | PHASE2 |
| NCT01164059 | COMPLETED | Schizophrenia |
University of Bremen |
2010-02 | PHASE4 |
| NCT01184443 | TERMINATED | Eating Disorder |
Children's Hospital of Eastern Ontario |
2010-08 | PHASE3 |
| NCT01592201 | TERMINATED | Schizophrenia |
Janssen Korea, Ltd., Korea |
2012-07 | PHASE4 |
| NCT00982020 | COMPLETED | Bipolar I Disorder; Schizophrenia |
Eli Lilly and Company |
2009-09 | PHASE4 |
| NCT01990755 | COMPLETED | Anorexia Nervosa; Bulimia Nervosa |
University of Turin, Italy |
2010-05 | |
| NCT01496183 | COMPLETED | Healthy |
State University of New York at Buffalo |
2007-10 | |
| NCT01593774 | COMPLETED | Schizophrenia |
Guilan University of Medical Sciences |
2012-05 | PHASE2 |
| NCT00816894 | COMPLETED | Schizophrenia |
Herzog Hospital |
2009-01 | PHASE2 |
| NCT00885690 | TERMINATED | Schizophrenia |
University of Aarhus |
2009-04 | |
| NCT01129674 | TERMINATED | Schizophrenia |
Eli Lilly and Company |
2010-06 | PHASE2; PHASE3 |
| NCT01491490 | TERMINATED | Schizophrenia |
GW Research Ltd |
2011-10 | PHASE2 |
| NCT01193166 | WITHDRAWN | Schizophrenia |
Ortho-McNeil Janssen Scientific Affairs, LLC |
2010-08 | PHASE4 |
| NCT01234779 | COMPLETED | Schizophrenia |
Hoffmann-La Roche |
2011-02 | PHASE2 |
| NCT00876772 | COMPLETED | Amyotrophic Lateral Sclerosis (ALS) |
Charite University, Berlin, Germany |
2011-03 | PHASE2; PHASE3 |
| NCT00988728 | WITHDRAWN | Schizophrenia |
Merck Sharp & Dohme LLC |
2011-02 | PHASE2 |
| NCT00910988 | COMPLETED | Hyperglycemia; Hyperlipidemia |
Washington University School of Medicine |
2009-02 | |
| NCT01052389 | COMPLETED | Schizophrenia |
Mario Negri Institute for Pharmacological Research |
2007-07 | PHASE4 |
| NCT00440843 | WITHDRAWN | Schizophrenia; Schizoaffective Disorder |
VA Connecticut Healthcare System |
2007-02 | PHASE3 |
| NCT00981526 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
University of Massachusetts, Worcester |
2009-03 | PHASE4 |
| NCT01607762 | COMPLETED | Healthy |
Janssen Research & Development, LLC |
2012-02 | PHASE1 |
| NCT00958568 | COMPLETED | Treatment Resistant Depression |
Eli Lilly and Company |
2009-08 | PHASE3 |
| NCT00844857 | COMPLETED | Bipolar Depression |
Eli Lilly and Company |
2009-04 | PHASE4 |
| NCT01207414 | COMPLETED | Schizophrenia |
Novartis |
2010-08 | PHASE4 |
| NCT00833300 | TERMINATED | Delirium; Agitation |
Richard Hall |
2008-06 | |
| NCT01503398 | COMPLETED | Fasting |
Dr. Reddy's Laboratories Limited |
2011-08 | PHASE1 |
| NCT01503424 | COMPLETED | Fed |
Dr. Reddy's Laboratories Limited |
2011-08 | PHASE1 |
| NCT00690235 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Diabetes; Weight Gain |
University of Texas Southwestern Medical Center |
2007-11 | PHASE4 |
| NCT01977300 | COMPLETED | Bipolar I Disorder |
University of British Columbia |
2003-01 | PHASE3 |
| NCT00682448 | COMPLETED | Metabolic Complications |
Rush University Medical Center |
2007-08 | PHASE4 |
| NCT00183404 | COMPLETED | Autism |
Drexel University |
2004-09 | PHASE2; PHASE3 |
| NCT00970281 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2009-09 | PHASE3 |
| NCT01485692 | COMPLETED | Psychomotor Agitation |
University of Sao Paulo |
2009-02 | |
| NCT01057849 | UNKNOWN | Schizophrenia |
Peking University |
2008-09 | |
| NCT00509067 | COMPLETED | Schizophrenia |
Georgetown University |
2007-11 | PHASE2 |
| NCT00205699 | COMPLETED | Aggression; Attention Deficit-Hyperactivity; Oppositional Defiant Disorder; Pervasive Development Disorders; Bipolar Disorder |
Washington University School of Medicine |
2006-04 | PHASE4 |
| NCT00363376 | COMPLETED | Weight Gain |
Lindner Center of HOPE |
2008-01 | PHASE3 |
| NCT00330863 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Northwell Health |
2006-05 | PHASE4 |
| NCT00741026 | COMPLETED | Insulin Resistance; Diabetes Mellitus |
Milton S. Hershey Medical Center |
2008-08 | |
| NCT00088465 | COMPLETED | Schizophrenic Disorders; Schizoaffective Disorder |
Eli Lilly and Company |
2004-08 | PHASE3 |
| NCT01168336 | COMPLETED | Healthy |
OBEcure Ltd. |
2010-07 | PHASE1 |
| NCT00512070 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Obesity; Metabolic Syndrome |
Seattle Institute for Biomedical and Clinical Research |
2007-07 | |
| NCT00245206 | COMPLETED | Schizophrenia; Alzheimer's Disease; Dementia |
Veterans Medical Research Foundation |
2005-08 | PHASE4 |
| NCT00692185 | COMPLETED | Eating Disorders |
New York State Psychiatric Institute |
2005-10 | PHASE2 |
| NCT00618748 | COMPLETED | Bipolar I Disorder |
Eli Lilly and Company |
2008-02 | PHASE3 |
| NCT00977301 | COMPLETED | HIV Infections |
Radboud University Medical Center |
2009-11 | PHASE1 |
| NCT00918021 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Niuvanniemi Hospital |
2009-06 | PHASE4 |
| NCT00186017 | COMPLETED | Bipolar Disorder |
Stanford University |
2005-07 | PHASE4 |
| NCT00845026 | COMPLETED | Schizophrenia |
Denovo Biopharma LLC |
2009-03 | PHASE2 |
| NCT00746785 | COMPLETED | Alcohol Dependence |
The Mind Research Network |
2002-09 | PHASE3 |
| NCT00490971 | COMPLETED | Bipolar Disorder |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2006-05 | PHASE3 |
| NCT00827918 | COMPLETED | Schizophrenia |
Merck Sharp & Dohme LLC |
2009-03 | PHASE2 |
| NCT01411930 | COMPLETED | Diabetes |
Veterans Medical Research Foundation |
2009-03 | PHASE4 |
| NCT00510146 | COMPLETED | Depression, Bipolar |
Eli Lilly and Company |
2007-08 | PHASE3 |
| NCT00384332 | COMPLETED | Bipolar Depression |
Vanderbilt University |
2007-01 | PHASE4 |
| NCT00446992 | COMPLETED | Schizophrenia |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2006-04 | PHASE1; PHASE2 |
| NCT00728195 | COMPLETED | Schizophrenia |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2008-11 | PHASE2 |
| NCT00932529 | COMPLETED | Psychotic Disorders |
University of Bergen |
2003-02 | PHASE4 |
| NCT00273624 | WITHDRAWN | Therapy-resistant Depression |
University Hospital Freiburg |
2005-06 | PHASE3 |
| NCT00615433 | COMPLETED | Schizophrenia |
Sumitomo Pharma America, Inc. |
2008-01 | PHASE3 |
| NCT00672464 | WITHDRAWN | Schizophrenia; Schizoaffective Disorder |
Duke University |
2008-04 | PHASE4 |
| NCT00895921 | COMPLETED | Diabetes |
Veterans Medical Research Foundation |
2008-11 | PHASE4 |
| NCT00737191 | WITHDRAWN | Hematopoietic/Lymphoid Cancer; Pain; Unspecified Adult Solid Tumor, Protocol Specific |
Mayo Clinic |
2008-08 | |
| NCT00423878 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
National Institute of Mental Health (NIMH) |
2007-01 | PHASE4 |
| NCT00770744 | COMPLETED | Schizophrenia |
H. Lundbeck A/S |
2008-09 | PHASE2 |
| NCT00320489 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2006-04 | PHASE3 |
| NCT00802100 | COMPLETED | Schizophrenia |
National Institute of Mental Health (NIMH) |
2008-12 | PHASE4 |
| NCT00439634 | TERMINATED | Schizophrenia |
Sanofi |
2007-02 | PHASE2 |
| NCT00287352 | COMPLETED | Psychotic Disorder; Schizophreniform Disorder; Schizophrenia; Schizoaffective Disorder; Mood Disorders With Psychotic Features |
University of North Carolina, Chapel Hill |
2005-05 | PHASE1 |
| NCT00394095 | COMPLETED | Bipolar Disorder; Weight Gain |
University of Cincinnati |
2006-12 | PHASE4 |
| NCT01864551 | COMPLETED | Bipolar Disorder |
Tri-Service General Hospital (TSGH) |
2008-08 | PHASE4 |
| NCT00797277 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Agitation |
National Taiwan University Hospital |
2006-07 | PHASE3 |
| NCT00188942 | COMPLETED | Major Depressive Disorder |
University Health Network, Toronto |
2005-02 | PHASE4 |
| NCT00266630 | COMPLETED | Manic or Mixed Episode Associated With Bipolar I Disorder |
Eli Lilly and Company |
2005-11 | PHASE3 |
| NCT00520507 | COMPLETED | Bipolar Disorder; Depression; Depressive Disorder |
Queen's University |
2007-10 | PHASE4 |
| NCT00645099 | COMPLETED | Schizophrenia |
Janssen-Cilag International NV |
2007-10 | PHASE3 |
| NCT00174265 | COMPLETED | Schizophrenia |
Organon and Co |
2005-07 | PHASE3 |
| NCT00391222 | COMPLETED | Bipolar Disorder |
Janssen Pharmaceutica N.V., Belgium |
2006-11 | PHASE3 |
| NCT00852956 | COMPLETED | Healthy |
OBEcure Ltd. |
2009-02 | PHASE1 |
| NCT00508157 | TERMINATED | Metabolic Syndrome; Schizophrenia |
Bristol-Myers Squibb |
2007-11 | PHASE4 |
| NCT00438776 | COMPLETED | Pathological Gambling |
Lindner Center of HOPE |
2007-02 | PHASE3 |
| NCT00044655 | COMPLETED | Schizophrenia |
Icahn School of Medicine at Mount Sinai |
2001-07 | PHASE4 |
| NCT00686998 | COMPLETED | Schizophrenia |
AstraZeneca |
2008-05 | PHASE2 |
| NCT00934908 | WITHDRAWN | Bipolar Disorder; Schizophrenia |
Medical University of South Carolina |
2009-03 | |
| NCT00129220 | COMPLETED | Bipolar Disorder |
Eli Lilly and Company |
2005-07 | PHASE3 |
| NCT01996501 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT01996488 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT03730857 | COMPLETED | Schizophrenia |
Calo Psychiatric Center |
2008-01 | PHASE1 |
| NCT00493233 | COMPLETED | Schizophrenia |
Centre for Addiction and Mental Health |
2006-11 | |
| NCT00734435 | TERMINATED | Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder |
Orexigen Therapeutics, Inc |
2008-09 | PHASE2 |
| NCT00515723 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Type 2 Diabetes Mellitus; Hyperglycemia |
Washington University School of Medicine |
2001-09 | |
| NCT00145496 | COMPLETED | Schizophrenia |
Organon and Co |
2004-12 | PHASE3 |
| NCT00520923 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2007-09 | PHASE2 |
| NCT00225498 | COMPLETED | Schizophrenia |
Northwell Health |
2002-06 | |
| NCT00401973 | COMPLETED | Schizophrenia; Schizoaffective Disorders |
Eli Lilly and Company |
2006-11 | PHASE3 |
| NCT00349973 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder |
University of Maryland, Baltimore |
2001-05 | |
| NCT00428168 | TERMINATED | Weight Gain |
OBEcure Ltd. |
2007-03 | PHASE2 |
| NCT00640510 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2008-03 | PHASE3 |
| NCT00056472 | COMPLETED | Major Depressive Disorder With Psychotic Features |
Weill Medical College of Cornell University |
2003-01 | PHASE3 |
| NCT00290121 | COMPLETED | Schizophrenia |
Université de Montréal |
2006-09 | PHASE4 |
| NCT00190749 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Eli Lilly and Company |
2003-10 | PHASE4 |
| NCT00001656 | COMPLETED | Childhood Schizophrenia; Psychotic Disorder; Schizophrenia |
National Institute of Mental Health (NIMH) |
1997-06 | PHASE4 |
| NCT00124930 | TERMINATED | Nausea; Neoplasms |
Alberta Health services |
2005-05 | PHASE3 |
| NCT00678457 | COMPLETED | Alcohol Dependence |
University of Virginia |
2007-01 | PHASE2 |
| NCT00259272 | COMPLETED | Bipolar Disorder I or II |
Eli Lilly and Company |
2005-11 | PHASE3 |
| NCT00275301 | COMPLETED | Borderline Personality Disorder |
University of Minnesota |
2005-12 | |
| NCT00864045 | COMPLETED | Schizophrenia |
H. Lundbeck A/S |
2007-03 | PHASE3 |
| NCT00759421 | COMPLETED | Schizophrenia |
H. Lundbeck A/S |
2006-10 | PHASE3 |
| NCT00759460 | COMPLETED | Schizophrenia |
H. Lundbeck A/S |
2007-03 | PHASE3 |
| NCT00176436 | COMPLETED | Schizophrenia |
University of Maryland, Baltimore |
2004-02 | PHASE4 |
| NCT00402324 | COMPLETED | Bipolar I Disorder |
Eli Lilly and Company |
2006-12 | PHASE4 |
| NCT00347425 | COMPLETED | Schizophrenia and Schizoaffective Disorder |
Solvay Pharmaceuticals |
2006-12 | PHASE3 |
| NCT00568672 | WITHDRAWN | Relapse Rate of a Major Depressive Episode; Safety of Olanzapine in Subjects With Major Depression |
Charite University, Berlin, Germany |
2007-10 | PHASE3 |
| NCT00926965 | COMPLETED | Tardive Dyskinesia; Neurocognitive Function |
Taipei Veterans General Hospital, Taiwan |
2003-01 | PHASE4 |
| NCT00265343 | COMPLETED | Schizophrenia |
Organon and Co |
2005-12 | PHASE3 |
| NCT00654576 | COMPLETED | Schizophrenia |
Central South University |
2005-02 | PHASE4 |
| NCT01149577 | COMPLETED | Schizophrenia; Sleep |
Central Institute of Psychiatry, Ranchi, India |
2007-08 | PHASE4 |
| NCT00337662 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder |
Eli Lilly and Company |
2006-05 | PHASE4 |
| NCT00303602 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Bipolar Disorder |
Eli Lilly and Company |
2006-03 | PHASE4 |
| NCT00396565 | COMPLETED | Schizophrenia |
Janssen Pharmaceutical K.K. |
2006-07 | PHASE3 |
| NCT00419653 | TERMINATED | Schizophrenia |
University of Jena |
2003-01 | PHASE4 |
| NCT00324051 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2006-05 | PHASE4 |
| NCT00636896 | COMPLETED | Weight Gain |
Neuropsychiatric Research Institute, Fargo, North Dakota |
2006-07 | |
| NCT00699946 | COMPLETED | Delirium |
The New England Baptist Hospital |
2005-01 | |
| NCT00512291 | COMPLETED | Advanced Cancer |
M.D. Anderson Cancer Center |
2005-06 | |
| NCT00329108 | TERMINATED | Acute Mania; Bipolar Disorder, Manic |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2006-11 | PHASE4 |
| NCT00351936 | COMPLETED | Schizophrenia |
North Suffolk Mental Health Association |
2005-12 | PHASE4 |
| NCT00216632 | COMPLETED | Schizophrenia; Psychotic Disorders |
Janssen Pharmaceutica N.V., Belgium |
2005-03 | PHASE4 |
| NCT00212836 | COMPLETED | Schizophrenia |
Organon and Co |
2005-04-21 | PHASE3 |
| NCT00223418 | COMPLETED | Schizophenia Disorder; Schizoaffective Disorder |
The University of Texas Health Science Center at San Antonio |
2004-01 | |
| NCT00179062 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Depressive Disorder, Major; Bipolar Disorder |
Vanderbilt University |
2000-02 | |
| NCT00156091 | COMPLETED | Schizophrenia |
Organon and Co |
2005-04 | PHASE3 |
| NCT00053703 | COMPLETED | Schizophrenia |
University of North Carolina, Chapel Hill |
2002-02 | PHASE4 |
| NCT00000374 | COMPLETED | Schizophrenia |
Northwell Health |
1998-09 | PHASE4 |
| NCT00183612 | TERMINATED | Bipolar Disorder; Psychotic Disorders |
Massachusetts General Hospital |
2000-05 | |
| NCT00159783 | COMPLETED | Bipolar Disorder |
Organon and Co |
2005-07 | PHASE3 |
| NCT00148564 | COMPLETED | Schizophrenia |
Charite University, Berlin, Germany |
2004-03 | PHASE4 |
| NCT01503450 | COMPLETED | Fed |
Dr. Reddy's Laboratories Limited |
2006-11 | PHASE1 |
| NCT00193713 | COMPLETED | Schizophrenia |
Solvay Pharmaceuticals |
2005-05 | PHASE3 |
| NCT01503437 | COMPLETED | Fasting |
Dr. Reddy's Laboratories Limited |
2006-11 | PHASE1 |
| NCT00205725 | COMPLETED | Schizophrenia; Type 2 Diabetes Mellitus |
Washington University School of Medicine |
2000-11 | |
| NCT01160991 | COMPLETED | Schizophrenia; Diabetes; Insulin Resistance |
Central Institute of Mental Health, Mannheim |
2004-05 | |
| NCT00205738 | COMPLETED | Schizophrenia; Type 2 Diabetes Mellitus |
Washington University School of Medicine |
2000-07 | |
| NCT00212771 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Organon and Co |
2004-09 | PHASE3 |
| NCT00685334 | COMPLETED | Eating Disorders |
New York State Psychiatric Institute |
2003-11 | PHASE4 |
| NCT00095524 | COMPLETED | Body Weight Change; Schizophrenia; Schizoaffective Disorder; Psychotic Disorder |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-03 | PHASE3 |
| NCT00048802 | COMPLETED | Bipolar Disorder |
Northwell Health |
2002-08 | PHASE4 |
| NCT00149292 | COMPLETED | Schizophrenia |
Denovo Biopharma LLC |
2005-08-23 | PHASE2 |
| NCT00260962 | COMPLETED | Anorexia Nervosa |
Ottawa Hospital Research Institute |
2000-09 | PHASE2 |
| NCT00143182 | COMPLETED | Bipolar Disorder |
Organon and Co |
2005-01-07 | PHASE3 |
| NCT00304616 | COMPLETED | Schizophrenia |
Korea Otsuka Pharmaceutical Co., Ltd. |
2004-10 | PHASE4 |
| NCT00048828 | COMPLETED | Schizophrenia |
Northwell Health |
2001-10 | PHASE4 |
| NCT00159744 | COMPLETED | Bipolar Disorder |
Organon and Co |
2004-11-30 | PHASE3 |
| NCT00156117 | COMPLETED | Schizophrenia |
Organon and Co |
2005-05-12 | PHASE3 |
| NCT00159796 | COMPLETED | Bipolar Disorder |
Organon and Co |
2004-12-14 | PHASE3 |
| NCT00212784 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Organon and Co |
2003-09-04 | PHASE3 |
| NCT00203307 | TERMINATED | Migraine |
Thomas Jefferson University |
2004-05 | |
| NCT00194064 | TERMINATED | Bipolar Disorder |
University Hospitals Cleveland Medical Center |
2002-07 | PHASE3 |
| NCT00151424 | COMPLETED | Schizophrenia |
Organon and Co |
2005-02-15 | PHASE3 |
| NCT00211562 | TERMINATED | Schizophrenia |
Augusta University |
2005-10 | PHASE3 |
| NCT00230828 | COMPLETED | Schizophrenia |
Solvay Pharmaceuticals |
2005-05 | PHASE3 |
| NCT00237913 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2004-07 | PHASE3 |
| NCT01234454 | COMPLETED | Schizophrenia |
University of North Carolina, Chapel Hill |
2002-01 | |
| NCT00183625 | COMPLETED | Schizophrenia |
University of California, Los Angeles |
2000-06 | PHASE4 |
| NCT00767715 | TERMINATED | Bipolar Disorder |
Eli Lilly and Company |
2004-10 | PHASE4 |
| NCT00235352 | COMPLETED | Schizophrenia |
North Suffolk Mental Health Association |
2002-02 | PHASE2; PHASE3 |
| NCT00034892 | COMPLETED | Schizophrenia; Psychotic Disorders; Mental Health; Mental Disorders |
AstraZeneca |
2002-03 | PHASE3 |
| NCT00592930 | COMPLETED | Anorexia Nervosa |
Northwell Health |
2000-06 | PHASE4 |
| NCT00625170 | COMPLETED | Insulin Resistance; Dyslipidemia |
Leiden University Medical Center |
2004-05 | |
| NCT00255879 | COMPLETED | Dyskinesia, Drug-Induced |
University of California, San Diego |
1999-01 | PHASE1 |
| NCT01123408 | COMPLETED | Schizophrenia |
Nathan Kline Institute for Psychiatric Research |
1999-06 | |
| NCT01282632 | COMPLETED | Subjects Had Unipolar, Non-psychotic Major Depression |
Sunnybrook Health Sciences Centre |
2002-08 | PHASE1; PHASE2 |
| NCT00182013 | COMPLETED | Bipolar Spectrum Disorder |
Massachusetts General Hospital |
2001-06 | PHASE4 |
| NCT00712686 | COMPLETED | Schizophrenia |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2000-06 | PHASE3 |
| NCT00621998 | COMPLETED | Neuroleptic-Induced Tardive Dyskinesia |
Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan |
2000-07 | PHASE4 |
| NCT00648921 | COMPLETED | Healthy |
Mylan Pharmaceuticals Inc |
2003-06 | PHASE1 |
| NCT00647777 | COMPLETED | Healthy |
Mylan Pharmaceuticals Inc |
2003-06 | PHASE1 |
| NCT00647972 | TERMINATED | Healthy |
Mylan Pharmaceuticals Inc |
2003-05 | PHASE1 |
| NCT00000373 | COMPLETED | Obsessive-Compulsive Disorder |
University of Florida |
1992-09 | PHASE4 |
| NCT00237861 | COMPLETED | Schizophrenia |
Yale University |
PHASE4 | |
| NCT00169065 | COMPLETED | Schizophrenia |
Harvard Medical School (HMS and HSDM) |
1998-08 | PHASE4 |
| NCT00007774 | COMPLETED | Schizoaffective Disorder; Schizophrenia |
US Department of Veterans Affairs |
1998-03 | PHASE4 |
| NCT00485680 | COMPLETED | Bipolar Disorder |
Eli Lilly and Company |
2003-12 | PHASE3 |
| NCT00231335 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Emory University |
2006-03 | PHASE4 |
| NCT00486005 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2003-02 | PHASE4 |
| NCT00485810 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2004-06 | PHASE1; PHASE2 |
| NCT01303601 | COMPLETED | Bipolar Disorder; Depression, Bipolar |
China Medical University, China |
2009-01 | PHASE4 |
| NCT00091650 | COMPLETED | Borderline Personality Disorder |
Eli Lilly and Company |
2004-03 | PHASE3 |
| NCT00150215 | COMPLETED | Schizophrenia |
Pfizer |
2005-07 | PHASE1 |
| NCT00179231 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Vanderbilt University |
2000-05 | |
| NCT00239109 | COMPLETED | Schizophrenia |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2003-04 | PHASE4 |
| NCT00103571 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2004-07 | PHASE4 |
| NCT00078039 | COMPLETED | Schizophrenia |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2004-03 | PHASE3 |
| NCT00297960 | COMPLETED | Healthy Male Volunteers |
Medical University of Vienna |
2005-04 | PHASE4 |
| NCT00259870 | COMPLETED | Schizophrenia |
GlaxoSmithKline |
2005-09 | PHASE2 |
| NCT00006195 | UNKNOWN | Schizophrenia |
National Center for Research Resources (NCRR) |
||
| NCT00182507 | COMPLETED | Trichotillomania |
Hamilton Health Sciences Corporation |
2000-06 | PHASE4 |
| NCT00036088 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2001-08 | PHASE4 |
| NCT00210769 | COMPLETED | Schizophrenia |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2004-01 | PHASE3 |
| NCT00089869 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
PHASE1; PHASE2 | |
| NCT00015548 | COMPLETED | Alzheimer's Disease |
National Institute of Mental Health (NIMH) |
2001-03 | |
| NCT00018668 | COMPLETED | Schizophrenia |
US Department of Veterans Affairs |
2000-10 | PHASE4 |
| NCT00088049 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2003-10 | PHASE4 |
| NCT00094549 | COMPLETED | Bipolar Disorder |
Eli Lilly and Company |
2004-10 | PHASE4 |
| NCT00100776 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Eli Lilly and Company |
2003-09 | PHASE4 |
| NCT00077714 | COMPLETED | Schizophrenia |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2004-01 | PHASE3 |
| NCT00485901 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2004-07 | PHASE3 |
| NCT00380224 | COMPLETED | Schizophrenia |
Wyeth is now a wholly owned subsidiary of Pfizer |
2006-07 | PHASE3 |
| NCT00088491 | COMPLETED | Schizophrenic Disorders |
Eli Lilly and Company |
2004-06 | PHASE3 |
| NCT00034580 | COMPLETED | Bipolar Disorder |
Eli Lilly and Company |
2001-08 | PHASE4 |
| NCT00065273 | COMPLETED | Mental Retardation; Developmental Delay Disorder |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
1998-07 | PHASE3 |
| NCT00057408 | COMPLETED | Autistic Disorder |
FDA Office of Orphan Products Development |
2003-05 | PHASE2 |
| NCT00287820 | COMPLETED | Schizophrenia; Diabetes; Metabolic Syndrome; Hyperglycemia |
Nathan Kline Institute for Psychiatric Research |
2004-02 | PHASE4 |
| NCT00159770 | COMPLETED | Schizophrenia; Schizoaffective Disorder; Psychotic Disorders |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2001-11 | PHASE3 |
| NCT00455442 | COMPLETED | Weight-Gain Prevention |
Corcept Therapeutics |
2007-03 | PHASE2 |
| NCT00050206 | COMPLETED | Bipolar Disorder |
Eli Lilly and Company |
2002-11 | PHASE4 |
| NCT00350467 | COMPLETED | Acute Schizophrenia |
Xian-Janssen Pharmaceutical Ltd. |
2006-06 | PHASE3 |
| NCT00088036 | COMPLETED | Borderline Personality Disorder |
Eli Lilly and Company |
2004-02 | PHASE3 |
| NCT00191828 | COMPLETED | Weight Gain |
Eli Lilly and Company |
2003-03 | PHASE4 |
| NCT00650793 | COMPLETED | Schizophrenia |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2004-03 | PHASE3 |
| NCT00485498 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2003-04 | PHASE4 |
| NCT00351000 | COMPLETED | Schizophrenia |
North Suffolk Mental Health Association |
2005-01 | PHASE4 |
| NCT00534183 | COMPLETED | Metabolic Syndrome; Diabetes; Obesity |
Central Institute of Psychiatry, Ranchi, India |
2006-06 | |
| NCT00145444 | COMPLETED | Schizophrenia; Psychotic Disorders |
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
2003-03 | PHASE3 |
| NCT00169702 | COMPLETED | Schizophrenia |
Heinrich-Heine University, Duesseldorf |
2003-06 | |
| NCT00182442 | COMPLETED | Schizophrenia |
Hamilton Health Sciences Corporation |
2003-10 | PHASE4 |
| NCT00014001 | COMPLETED | Schizophrenia |
National Institute of Mental Health (NIMH) |
2000-12 | PHASE4 |
| NCT00083668 | COMPLETED | Schizophrenia |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2004-04 | PHASE3 |
| NCT00331825 | COMPLETED | Schizophrenia; Extrapyramidal Syndrome |
Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan |
2000-07 | PHASE4 |
| NCT00191399 | COMPLETED | Depression, Bipolar |
Eli Lilly and Company |
2004-05 | PHASE4 |
| NCT00378183 | COMPLETED | Schizoaffective Disorder; Schizophrenia |
Janssen, LP |
2001-02 | PHASE4 |
| NCT00236379 | COMPLETED | Schizophrenia; Diabetes Mellitus |
Janssen, LP |
PHASE4 | |
| NCT00071253 | TERMINATED | Bipolar Disorder |
Abbott |
2003-07 | PHASE4 |
| NCT00418171 | COMPLETED | Schizophrenia |
Pfizer |
2002-02 | PHASE4 |
| NCT00113594 | COMPLETED | Schizophrenia; Bipolar Disorder |
Eli Lilly and Company |
2005-06 | PHASE3 |
| NCT00094640 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Eli Lilly and Company |
PHASE1 | |
| NCT00044187 | COMPLETED | Schizophrenia; Psychotic Disorders; Bipolar Disorder |
Eli Lilly and Company |
2001-04 | PHASE4 |
| NCT00108368 | COMPLETED | Schizophrenia; Psychotic Disorders |
US Department of Veterans Affairs |
2003-10 | PHASE4 |
| NCT00088478 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2004-06 | PHASE3 |
| NCT00221481 | WITHDRAWN | Bipolar Disorder |
Mayo Clinic |
PHASE4 | |
| NCT00177567 | COMPLETED | Bipolar Disorder |
University of Pittsburgh |
2001-07 | PHASE4 |
| NCT00433121 | COMPLETED | Dementia |
Sykehuset Innlandet HF |
2006-09 | PHASE4 |
| NCT00236457 | COMPLETED | Schizophrenia; Psychotic Disorders |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2000-11 | PHASE3 |
| NCT00316238 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2006-04 | PHASE2 |
| NCT00208819 | COMPLETED | Senile Dementia, Alzheimer Type; Dementia, Alzheimer Type; Alzheimer Disease; Dementia |
Emory University |
2003-09 | PHASE4 |
| NCT00191555 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2003-08 | PHASE4 |
| NCT00090012 | COMPLETED | Schizophrenia; Schizoaffective Disorder |
Eli Lilly and Company |
2004-07 | PHASE4 |
| NCT00035321 | COMPLETED | Major Depressive Disorder |
Eli Lilly and Company |
2002-04 | PHASE3 |
| NCT00051298 | COMPLETED | Schizophrenia |
Eli Lilly and Company |
2002-11 | PHASE3 |
| NCT00483964 | COMPLETED | Schizophrenia |
Q.Mundewadi Ayurvedic Research & Charitable Trust |
2005-09 | PHASE2 |
| NCT00222495 | COMPLETED | Psychotic Disorders; Schizophrenia; Schizophreniform Disorders; Schizoaffective Disorders |
University of Minnesota |
2002-08 | |
| NCT00485771 | COMPLETED | Bipolar Disorder |
Eli Lilly and Company |
2003-11 | PHASE4 |
| NCT00073164 | COMPLETED | Schizophrenia |
Abbott |
2003-07 | PHASE2 |
| NCT00034801 | COMPLETED | Depression; Schizophrenia; Schizoaffective Disorder |
Eli Lilly and Company |
2001-09 | PHASE4 |
| NCT00181935 | COMPLETED | Bipolar Disorder; Mania |
Massachusetts General Hospital |
2001-03 | PHASE4 |
| NCT00191997 | COMPLETED | Bipolar Disorder |
Eli Lilly and Company |
2004-10 | PHASE4 |
| NCT00265551 | COMPLETED | Schizophrenia |
Wyeth is now a wholly owned subsidiary of Pfizer |
2006-01 | PHASE2 |
| NCT00190892 | COMPLETED | Bipolar Disorder |
Eli Lilly and Company |
2004-09 | PHASE4 |
| NCT00485823 | COMPLETED | Schizophrenic Disorders |
Eli Lilly and Company |
2002-12 | PHASE4 |
(data from https://clinicaltrials.gov, updated on 2026-05-26)
Check the
Olanzapine
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.